Table 2_Brain radiotherapy added to first-line immunochemotherapy improves survival in pat

172 patient records from a retrospective cohort study comparing immunochemotherapy with and without brain radiotherapy. The data includes overall survival, intracranial progression-free survival, and objective response rates for treatment-naïve, driver-negative lung adenocarcinoma patients with synchronous brain metastases. The dataset was authored by Rui Wang and last updated on 2026-03-26.

Use Cases

• Compare overall survival outcomes based on treatment group assignment mentioned in the description
• Analyze intracranial progression-free survival (iPFS) based on the reported hazard ratios and median durations
• Model objective response rates (iORR/eORR) for patients receiving combined therapy versus systemic therapy alone
• Assess the safety profile of combined immunochemotherapy and radiotherapy based on the reported toxicity data

Strengths

• Data is derived from a study with 172 patients, providing a specific cohort size
• Includes key clinical endpoints with specific median values (e.g., 23.5 vs. 17.5 months OS) and hazard ratios
• Results are supported by multivariate analysis verifying brain radiotherapy as an independent favorable factor

Limitations

• Row count is unknown, which may limit suitability assessment
• Column-level documentation is absent; field semantics must be inferred after download
• Data may reflect temporal or institutional bias inherent to the single retrospective study design

Provenance

Source

figshare, author Rui Wang

Collection Method

Retrospective cohort study

Freshness

Last updated 2026-03-26 05:16:53; freshness should be verified